Biocept Financial Statements From 2010 to 2025

BIOCQ Stock   0.0001  0.0001  50.00%   
Analyzing historical trends in various income statement and balance sheet accounts from Biocept's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Biocept's valuation are summarized below:
Gross Profit
-14.3 M
Market Capitalization
525
Enterprise Value Revenue
0.0417
Revenue
1.4 M
Earnings Share
(96.34)
There are currently one hundred twenty fundamental signals for Biocept that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Biocept's prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 12/27/2025, Market Cap is likely to drop to about 3.3 M. In addition to that, Enterprise Value is likely to drop to about 2.4 M

Biocept Total Revenue

33.03 Million

Check Biocept financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocept's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 300.3 K or Selling General Administrative of 12.6 M, as well as many indicators such as Price To Sales Ratio of 0.13, Dividend Yield of 0.0 or PTB Ratio of 0.32. Biocept financial statements analysis is a perfect complement when working with Biocept Valuation or Volatility modules.
  
Build AI portfolio with Biocept Stock
Check out the analysis of Biocept Correlation against competitors.
To learn how to invest in Biocept Stock, please use our How to Invest in Biocept guide.

Biocept Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets43 M35.5 M26.6 M
Slightly volatile
Short and Long Term Debt Total10.9 M13.9 M6.2 M
Slightly volatile
Other Current Liabilities2.2 M2.6 MM
Slightly volatile
Total Current Liabilities7.1 MM6.4 M
Slightly volatile
Total Stockholder Equity9.7 M10.2 M13.2 M
Pretty Stable
Property Plant And Equipment Net12.8 M16.3 M7.8 M
Slightly volatile
Current Deferred Revenue0.80.90.9813
Slightly volatile
Accounts Payable1.3 M1.4 M2.6 M
Pretty Stable
Cash18 M14.8 M12.2 M
Slightly volatile
Non Current Assets Total13.2 M16.7 M7.9 M
Slightly volatile
Cash And Short Term Investments18 M14.8 M12.2 M
Slightly volatile
Net Receivables1.8 M1.9 M4.5 M
Very volatile
Common Stock Shares Outstanding418.4 K649.9 K235.9 K
Slightly volatile
Liabilities And Stockholders Equity43 M35.5 M26.6 M
Slightly volatile
Non Current Liabilities Total11 M19 M5.9 M
Slightly volatile
Capital Lease Obligations10.8 M13.8 M6.2 M
Slightly volatile
Inventory1.7 M870.5 KM
Slightly volatile
Other Current Assets675.3 K484.2 K483.7 K
Slightly volatile
Other Stockholder Equity317.7 M353.4 M277.9 M
Slightly volatile
Total Liabilities20.7 M25.3 M12.6 M
Slightly volatile
Net Invested Capital9.8 M10.3 M13.2 M
Pretty Stable
Property Plant And Equipment Gross18 M22.4 M12.4 M
Slightly volatile
Total Current Assets29.8 M18.8 M18.7 M
Slightly volatile
Capital Stock1.5 K2.3 KK
Slightly volatile
Net Working Capital20.1 M12.5 M12 M
Slightly volatile
Short Term Debt2.3 MM1.8 M
Slightly volatile
Common Stock2.2 K1.8 K4.1 K
Slightly volatile
Non Currrent Assets Other338.1 K347.4 K412.4 K
Slightly volatile
Short and Long Term Debt93.6 K105.3 K114.8 K
Slightly volatile
Non Current Liabilities Other4.9 M5.5 MM
Slightly volatile

Biocept Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.9 M1.1 M
Slightly volatile
Interest Expense300.3 K363.4 K270.1 K
Slightly volatile
Selling General Administrative12.6 M18.5 M9.7 M
Slightly volatile
Selling And Marketing Expenses7.6 M8.2 M6.5 M
Slightly volatile
Total Revenue33 M29.7 M16.2 M
Slightly volatile
Other Operating Expenses53.1 M66.5 M39.2 M
Slightly volatile
Research Development5.8 M7.1 M5.1 M
Slightly volatile
Cost Of Revenue27.1 M32.7 M17.8 M
Slightly volatile
Total Operating Expenses26 M33.8 M21.4 M
Slightly volatile
Reconciled Depreciation1.4 M1.9 M1.1 M
Slightly volatile

Biocept Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.1 M3.7 M1.5 M
Slightly volatile
Begin Period Cash Flow34.9 M33.2 M11.5 M
Slightly volatile
Depreciation1.7 M1.9 M1.1 M
Slightly volatile
Other Non Cash Items986.5 K567.9 K1.5 M
Slightly volatile
Capital Expenditures1.1 M928 K839.3 K
Slightly volatile
Issuance Of Capital Stock205.2 K216 K18.5 M
Slightly volatile
End Period Cash Flow18 M14.8 M12.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.130.11581.7 K
Slightly volatile
Days Sales Outstanding33.1734.92293
Slightly volatile
Average Payables4.9 M4.7 M2.7 M
Slightly volatile
Stock Based Compensation To Revenue0.140.124817.7381
Slightly volatile
Capex To Depreciation0.670.440.7773
Very volatile
Inventory Turnover35.533.8121.3183
Slightly volatile
Days Of Inventory On Hand10.6111.1720.3122
Slightly volatile
Payables Turnover17.6516.817.3487
Slightly volatile
Sales General And Administrative To Revenue0.680.72330
Slightly volatile
Average Inventory495.1 K471.5 K362.5 K
Slightly volatile
Research And Ddevelopement To Revenue0.260.271.1 K
Slightly volatile
Capex To Revenue0.03410.035935.353
Slightly volatile
Cash Per Share24.9326.243.6 K
Slightly volatile
Days Payables Outstanding21.3522.482.8 K
Slightly volatile
Current Ratio1.512.671.8653
Slightly volatile
Receivables Turnover9.3713.828.6054
Pretty Stable
Capex Per Share1.561.64448
Slightly volatile
Average Receivables13.2 M12.6 M5.1 M
Slightly volatile
Revenue Per Share49.9952.62539
Pretty Stable
Interest Debt Per Share24.0225.2824.6 K
Slightly volatile
Debt To Assets0.430.452.3934
Slightly volatile
Operating Cycle43.7946.09311
Slightly volatile
Days Of Payables Outstanding21.3522.482.8 K
Slightly volatile
Ebt Per Ebit1.21.161.0948
Very volatile
Quick Ratio1.422.551.7648
Slightly volatile
Net Income Per E B T1.11.151.0141
Slightly volatile
Cash Ratio1.092.111.3669
Slightly volatile
Days Of Inventory Outstanding10.6111.1720.3122
Slightly volatile
Days Of Sales Outstanding33.1734.92293
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.091.221.0176
Very volatile
Fixed Asset Turnover1.031.651.2476
Slightly volatile
Debt Ratio0.430.452.3934
Slightly volatile
Price Sales Ratio0.130.11581.7 K
Slightly volatile
Asset Turnover0.790.750.4286
Slightly volatile

Biocept Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.3 M3.4 M14 M
Slightly volatile
Enterprise Value2.4 M2.5 M11.3 M
Slightly volatile

Biocept Fundamental Market Drivers

About Biocept Financial Statements

Biocept shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Biocept investors may analyze each financial statement separately, they are all interrelated. The changes in Biocept's assets and liabilities, for example, are also reflected in the revenues and expenses on on Biocept's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.80 
Total Revenue29.7 M33 M
Cost Of Revenue32.7 M27.1 M
Stock Based Compensation To Revenue 0.12  0.14 
Sales General And Administrative To Revenue 0.72  0.68 
Research And Ddevelopement To Revenue 0.27  0.26 
Capex To Revenue 0.04  0.03 
Revenue Per Share 52.62  49.99 
Ebit Per Revenue(1.11)(1.17)

Pair Trading with Biocept

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biocept position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biocept will appreciate offsetting losses from the drop in the long position's value.

Moving against Biocept Stock

  0.39EQ EquilliumPairCorr
  0.39688578 Shanghai Allist PharPairCorr
The ability to find closely correlated positions to Biocept could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biocept when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biocept - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biocept to buy it.
The correlation of Biocept is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biocept moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biocept moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biocept can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Biocept Stock Analysis

When running Biocept's price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.